LOGIN  |  REGISTER

List of Diagnostics & Research Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 489.77
-4.33 -0.88
1.42M
386.37M
US$ 189.230B
US$ 217.49
-1.43 -0.65
2.53M
738.93M
US$ 160.710B
US$ 116.97
-1.92 -1.61
2.27M
381.67M
US$ 44.640B
US$ 531.35
8.27 1.58
490,096
83.05M
US$ 44.130B
US$ 215.28
0.29 0.13
579,233
182.50M
US$ 39.290B
US$ 127.20
-1.48 -1.15
1.17M
292.12M
US$ 37.160B
US$ 1.00
-9.50 -0.86
126,484
21.68M
US$ 23.640B
US$ 272.46
4.27 1.59
726,188
82.33M
US$ 22.430B
US$ 216.60
-1.03 -0.47
496,845
84.90M
US$ 18.390B
US$ 112.94
-4.19 -3.58
1.99M
158.80M
US$ 17.930B
US$ 292.14
-1.24 -0.42
366,203
59.13M
US$ 17.270B
US$ 135.91
0.69 0.51
677,431
112.44M
US$ 15.280B
US$ 64.72
-0.24 -0.37
1.25M
180.85M
US$ 11.700B
US$ 91.02
-0.66 -0.72
413,449
123.41M
US$ 11.230B
US$ 204.46
1.69 0.83
501,392
51.30M
US$ 10.490B
US$ 41.77
-0.25 -0.59
1.25M
228.18M
US$ 9.530B
US$ 283.19
1.74 0.62
168,745
30.68M
US$ 8.690B
US$ 58.15
0.21 0.36
942,013
120.15M
US$ 6.990B
US$ 73.71
5.18 7.56
929,609
68.49M
US$ 5.050B
US$ 66.02
-0.65 -0.97
710,258
66.82M
US$ 4.410B
US$ 14.40
0.29 2.06
318,495
282.62M
US$ 4.070B
US$ 18.18
-0.17 -0.93
1.55M
216.31M
US$ 3.930B
US$ 25.85
0.00 0.00
563,387
124.34M
US$ 3.210B
US$ 25.74
-0.52 -1.98
1.09M
117.99M
US$ 3.040B
US$ 36.22
0.20 0.56
411,968
67.89M
US$ 2.460B
US$ 18.34
0.40 2.23
559,047
127.47M
US$ 2.340B
US$ 8.59
0.21 2.51
2.81M
267.44M
US$ 2.300B
US$ 18.52
0.12 0.65
451,884
89.64M
US$ 1.660B
US$ 26.98
0.57 2.16
1.56M
57.67M
US$ 1.560B
US$ 1.63
0.03 1.88
1.08M
773.06M
US$ 1.260B
US$ 41.50
0.04 0.10
105,758
24.56M
US$ 1.020B
US$ 27.08
0.48 1.80
182,912
29.63M
US$ 802.380M
US$ 20.17
0.87 4.51
195,443
26.91M
US$ 542.770M
US$ 9.81
0.08 0.82
753,123
54.10M
US$ 530.720M
US$ 0.87
0.03 3.17
3.59M
311.61M
US$ 272.160M
US$ 1.57
0.02 1.29
506,722
121.79M
US$ 191.210M
US$ 2.24
-0.11 -4.68
752,161
79.40M
US$ 177.860M
US$ 0.57
-0.0015 -0.26
3.83M
286.49M
US$ 163.990M
US$ 1.56
-0.03 -1.89
69,636
90.48M
US$ 141.150M
US$ 4.34
-0.71 -14.06
1.86M
30.37M
US$ 131.810M
US$ 3.68
0.01 0.27
3,913
31.62M
US$ 116.360M
C$ 0.40
-0.005 -1.25
68,576
278.58M
C$ 110.040M
US$ 3.39
0.11 3.35
21,674
27.29M
US$ 92.510M
US$ 3.38
0.28 9.03
205,372
25.78M
US$ 87.140M
US$ 0.77
-0.02 -2.80
28,733
102.68M
US$ 78.860M
US$ 4.89
-0.16 -3.17
60,576
14.55M
US$ 71.150M
US$ 1.27
0.06 4.96
60,404
50.49M
US$ 64.120M
US$ 1.47
-0.05 -3.29
1.04M
38.84M
US$ 57.090M
US$ 1.83
0.03 1.67
72,435
28.93M
US$ 52.940M
C$ 0.49
-0.01 -2.00
83,500
105.78M
C$ 51.830M
US$ 1.87
0.07 3.89
107,122
27.21M
US$ 50.880M
US$ 1.47
0.02 1.38
2.68M
34.24M
US$ 50.330M
US$ 0.64
-0.02 -3.09
137,039
78.69M
US$ 50.100M
US$ 3.63
-0.15 -3.97
48,806
10.34M
US$ 37.530M
US$ 1.22
0.00 0.00
58,674
30.58M
US$ 37.310M
US$ 1.36
0.02 1.49
12,488
26.33M
US$ 35.810M
US$ 1.26
0.01 0.80
2,898
27.87M
US$ 35.120M
US$ 1.59
-0.06 -3.64
28,852
17.05M
US$ 27.110M
C$ 0.28
0.00 0.00
0
83.29M
C$ 23.320M
US$ 1.12
-0.02 -1.33
255,509
20.36M
US$ 22.700M
US$ 0.55
0.04 7.84
32,878
38.21M
US$ 21.020M
US$ 2.92
-0.07 -2.34
2,231
5.80M
US$ 16.940M
C$ 0.16
0.00 0.00
0
99.64M
C$ 15.940M
US$ 2.70
-0.02 -0.74
7,338
5.85M
US$ 15.800M
US$ 0.10
-0.0029 -2.88
4.59M
161.02M
US$ 15.730M
US$ 3.76
0.06 1.62
115,691
4.05M
US$ 15.230M
US$ 1.41
-0.11 -7.24
37,084
9.50M
US$ 13.400M
US$ 1.50
0.12 8.70
164,581
8.45M
US$ 12.680M
C$ 0.17
-0.01 -5.56
8,475
71.31M
C$ 12.120M
US$ 0.88
-0.20 -18.43
157,535
13.66M
US$ 12.030M
US$ 0.58
-0.02 -3.51
243,800
19.24M
US$ 11.060M
US$ 1.11
-0.10 -8.26
292,240
8.84M
US$ 9.810M
US$ 6.50
-0.12 -1.81
1,761
1.42M
US$ 9.230M
C$ 0.14
0.00 0.00
40,220
54.70M
C$ 7.660M
C$ 0.07
0.005 8.33
127,000
94.47M
C$ 6.140M
C$ 0.05
-0.005 -10.00
9,000
122.72M
C$ 5.520M
US$ 0.51
-0.04 -6.56
58,014
9.08M
US$ 4.670M
US$ 0.40
-0.01 -3.01
166,764
10.01M
US$ 4.000M
US$ 3.97
-0.21 -5.02
45,784
690,247
US$ 2.740M
US$ 6.60
0.00 0.00
0
380,648
US$ 2.510M
C$ 0.02
0.00 0.00
58,000
122.77M
C$ 1.840M
US$ 0.43
0.00 0.00
0
2.63M
US$ 1.140M
US$ 4.10
-0.15 -3.53
6,396
-
US$ -

Latest News From Diagnostics & Research Stocks


IDEXX Laboratories Schedules Two Institutional Investor Events

WESTBROOK, Maine / Dec 07, 2023 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming institutional investor events: Thursday, January 4, 2024, 1:30 pm EST - Jay Mazelsky, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference in New York, New York. Monday, January 15, 2024, 1:00 pm EST - Jay Mazelsky... Read more


Quest Diagnostics and CDC Expand Public Health Research Collaboration to Better Understand Hepatitis C Burden in the United States

Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C SECAUCUS, N.J., Dec. 7, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been awarded a contract by the United States Centers for Disease Control and Prevention (CDC) designed to assess the burden of hepatitis... Read more


iSpecimen Strengthens Global Oncology Biospecimen Offering

LEXINGTON, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addition of several new suppliers, expanded relationships with existing suppliers and new offerings to increase access to critically important biospecimens for advancing biomedical research... Read more


Applied DNA Sciences Announces Fourth Quarter Fiscal Year 2023 Financial Results

Conference Call/Webcast Scheduled for Today at 4:30 PM ET  STONY BROOK, NY / ACCESSWIRE / December 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its fourth quarter ended September 30, 2023. "Our fiscal fourth quarter concludes a productive year during which we took a number of critical steps that place us firmly in the execution phase... Read more


Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump

With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems3,4 The clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when the system is connected to Dexcom CGM technology5 SAN DIEGO / Dec 06, 2023 / Business Wire / DexCom, Inc. (Nasdaq: DXCM), the global leader in... Read more


Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Includes new data from prospective clinical trials in HR+/HER2- breast cancer evaluating treatment on molecular recurrence (TOMR) and additional real-world data across all breast cancer subtypes AUSTIN, Texas / Dec 06, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2023 San Antonio Breast... Read more


Sera Prognostics Announces Primary Endpoint Criteria Met In Pivotal Prime Study Interim Look - Enrollment To Stop Due To Success

SALT LAKE CITY, Dec. 6, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy,... Read more


Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma Platform migration to begin on the Company’s EndoMDx™ test for broader endometriosis indications AUSTIN, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic... Read more


Bionano Genomics Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting

A platform presentation will feature Dr. Enze Liu from the Indiana University School of Medicine sharing findings from a study on the use of optical genome mapping (OGM) to detect structural variants (SVs) in multiple myeloma Thirteen scientific posters featuring results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and hematological malignancy research will be presented at the conference SAN DIEGO, Dec.... Read more


Waters Opens New State-of-the-Art Global Capability Center in Bengaluru, India

News Summary: Waters inaugurates Global Capability Center in Bengaluru's RMZ Ecoworld technology park with dignitaries from government, customers, partners, and employees. New US$16M (INR ₹1.3Bn) facility will employ 300+ for roles enabling leading-edge software engineering, technology and product development, data analytics and IT. The Global Capability Center will enable Waters to accelerate technology and software development, digitization, operational excellence,... Read more


Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Groundbreaking Results Demonstrate Sensitivity for Colorectal Cancer of 97% with Specificity of 97% and Advanced Adenoma Sensitivity of 82% Results Exceed those from the Company’s European ColoFuture Clinical Study of the Same Design ColoFuture and eAArly DETECT Studies Support Inclusion of a Portfolio of Novel mRNA Biomarkers in Pivotal FDA PMA Clinical Trial (ReconAAsense); Trial is On Track to Commence Enrollment in Mid-2024 BERKELEY, Calif. and MAINZ, Germany,... Read more


Neogen® Announces Biosecurity Partnership with TerraNova

LEXINGTON, Ky., Dec. 5, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has partnered with the TerraNova Equestrian Center in Myakka City, Florida, making the company the official biosecurity provider of the facility. TerraNova Equestrian Center, a premier Florida equestrian destination, is designed to deliver an unparalleled experience for competitors and horses while keeping safety a priority. The equestrian center features multiple... Read more


National Employer Selects DarioHealth Cardiometabolic and GLP-1 Solutions to Improve Employee Health

New client will use Dario's integrated approach to support long-term behavior change for employees living with diabetes, pre-diabetes, hypertension and those taking a GLP-1 medication NEW YORK, Dec. 5, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide cardiometabolic and GLP-1 solutions to a national employer (the "Employer") beginning in January... Read more


NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS). RaDaR data will be presented during a Poster Spotlight Session featuring an updated analysis of the TRACER study, which assessed patients with early-stage breast cancer across... Read more


RadNet Launches a Pilot Inside Walmart of its New MammogramNow™ Offering

LOS ANGELES, Dec. 05, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces MammogramNow, an innovative screening mammography service set to debut at the Walmart Supercenter in Milford, Delaware, on December 8th. This pioneering initiative aims to enhance breast health awareness and accessibility, including the integration of cutting-edge DeepHealth® (de... Read more


VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre

HENDERSON, Nev., Dec. 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A. ("WE") in Belgium. Volition will use the proceeds from the financing for ongoing development of its Nu.Q® product portfolio, including taking forward its clinical and regulatory program for Nu.Q® NETs, which... Read more


bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

SAN ANTONIO / Dec 05, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today announced the appointment of Jamie Platt, Ph.D., to its Board of Directors effective Dec. 1, 2023. Dr. Platt has two decades of experience bringing novel diagnostic technologies to global markets. “Dr. Platt’s impressive track record in transforming... Read more


Neuronetics: NeuroStar TMS Receives Expanded Regulatory Approval in Japan

MALVERN, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved multiple proprietary innovations, which significantly advance the patient treatment experience with the NeuroStar TMS (transcranial... Read more


BioMark Diagnostics Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay

Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that the Canadian Intellectual Property Office (CIPO) has granted patent N° 2.906.236, on October 31, 2023. This patent entitled "Detection and... Read more


Agilent Technologies BioTek Cytation C10 Confocal Imaging Reader Enhanced with Innovative Water Immersion Technology

Empowering researchers with superior imaging performance for cutting-edge live-cell and three-dimensional applications SANTA CLARA, Calif. / Dec 04, 2023 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader. These features improve image quality and results by reducing deleterious effects on live-cell samples and enhancing clarity... Read more


Spectral Medical Provides November Tigris Trial Update

79 patients enrolled TORONTO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update for the month of November on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and... Read more


Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities

Mission-focused collaboration to explore opportunities to help accelerate the discovery and development of cancer drugs and diagnostics for patients LONDON & PALO ALTO, Calif. / Dec 04, 2023 / Business Wire / Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration to explore the... Read more


Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score® results to refine distant recurrence risk estimates New concordance analysis supporting the generation of Oncotype DX® results from core needle biopsy to personalize treatment decisions ADAPTcycle trial data, using Oncotype DX results and endocrine response to stratify patients, may expand the number of breast cancer patients able to forgo chemotherapy post-surgery;... Read more


DNA Labs International solves significant cold cases with QIAGEN workflow for forensic genetic genealogy

Venlo, the Netherlands, and Deerfield Beach, Florida, Nov. 30, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DNA Labs International announced today that DLI has recently solved two decades-old “cold cases” using QIAGEN solutions. The products involved are ForenSeq Kintelligence System for forensic genetic genealogy, in conjunction with the GEDmatch database, highlighting the effectiveness and growing adoption of this new approach to... Read more


Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection

Spotlight sessions highlight role of Guardant blood tests in tissue-free detection of minimal residual disease and predictive impact of ctDNA genomic profiling MRD study found ctDNA detection after adjuvant therapy using Guardant Reveal™ was prognostic for distant recurrence of cancer nearly eight months before detected via standard of care surveillance PALO ALTO, Calif. / Nov 30, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology... Read more


CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024

SAN ANTONIO, / Nov 30, 2023 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year. “CyPath® Lung, our noninvasive test for... Read more


Bionano Laboratories Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD). The publication describes the evaluation of an OGM-based laboratory developed test (LDT) including... Read more


Burning Rock Biotech Reports Third Quarter 2023 Financial Results

GUANGZHOU, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Personalized Minimal Residual Disease (MRD)... Read more


ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Intellectual Property Portfolio Now Stands at 71 Globally Issued Patents ANN ARBOR, Mich. / Nov 29, 2023 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No. 11828727 (the ‘727 patent) titled “Thermoacoustic Probe.” The ‘727 patent relates to a thermoacoustic probe design with an optical... Read more


Bionano Genomics Announces Publication Demonstrating Utility of OGM to Assess Genome Integrity of CRISPR-Edited Cells as Part of Gene Therapy Development

SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations (SVs) introduced by CRISPR-Cas9 gene editing of CD4+ T-cells that could potentially limit the therapeutic use of such edited cells. The research study authors used OGM in combination with drop-off digital PCR (ddPCR) to assess genome integrity of cells that were edited... Read more


Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its presentation at the 35th Annual Piper Sandler Healthcare Conference, to be delivered by Chief Executive Officer, Guido Baechler and Bill Caragol, Chief Financial Officer, will be available to view live and post event via webcast... Read more


LevelJump Healthcare Reports Third Quarter 2023 Results

Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30, 2023. All amounts are expressed in Canadian dollars. Financial and Operational Highlights Revenues from operations were $2,856,044 for the third quarter,... Read more


Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis

Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technology SECAUCUS, N.J. and WALTHAM, Mass., Nov. 28, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Scipher Medicine, a precision immunology company, today announced a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine... Read more


Applied DNA Sciences Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application

STONY BROOK, NY / ACCESSWIRE / November 28, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the receipt of a follow-on order for Linea™ DNA valued above the mid-six figures. The order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA (non-therapeutic) for a global manufacturer of in vitro diagnostics (IVD). Under the terms of the repeat order,... Read more


Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences

WALTHAM, Mass. & CAMBRIDGE, Mass. / Nov 28, 2023 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, today announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis. Through this collaboration, Thermo Fisher and Flagship will work together to create new platform companies focusing on novel... Read more


Charles River Laboratories and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration

Company will perform plasmid DNA production in support of early phase trials for SPG56 Hereditary Spastic Paraplegia WILMINGTON, Mass. / Nov 28, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures for rare diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO)... Read more


Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)

AUSTIN, Texas, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that California Medicaid (Medi-Cal) added Ova1Plus® to its fee schedule. Aspira will be reimbursed at a rate of $897 for all Ova1Plus® tests processed for Medi-Cal patients... Read more


BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

ELMWOOD PARK, N.J., Nov. 28, 2023 /PRNewswire/ -- BioReference® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pioneer in providing accessible, quality real world data ("RWD") for the pharmaceutical and life science industries. This collaborative arrangement will offer healthcare providers and researchers unique solutions to inform clinical studies and improve patient outcomes. Combining... Read more


Keystone Dental Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Q3 revenue increased 18.9% year-over-year to $16.8M, including $11.9M from the U.S. Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Meeting on Monday, December 18th, 2023 IRVINE, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings (“Keystone Dental” or the “Company”), a pioneer in dental implant technology, announced today financial results and provided a corporate update for the... Read more


BioMark Diagnostics Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers today reports strong operational results from the second quarter ended September 30, 2023. The Company also announces that it intends to extend the warrant exercise term in a continuing effort to improve corporate value... Read more


Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®

Working together to bring rapid, automated microbial identification directly from positive blood culture samples TUCSON, Ariz., Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification. This agreement enables... Read more


Charles River Laboratories to Present at Evercore ISI Investor Conference

WILMINGTON, Mass. / Nov 27, 2023 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th, at 9:10 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations... Read more


DarioHealth Contracts with New Employer for Cardiometabolic Solution

Demand for Dario's integrated cardiometabolic solution continues to grow as employers grappling with the surge in GLP-1 medication utilization search for proven ways to change health behaviors NEW YORK, Nov. 27, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract to provide its cardiometabolic solution to an employer (the "Employer") beginning in January... Read more


RadNet Unveils DeepHealth, a Pioneering AI-Powered Health Informatics Portfolio

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces the launch of DeepHealth, a health informatics portfolio designed to dramatically drive efficiency and transform radiology’s role in healthcare. Radiology is embracing an increasing responsibility in healthcare screening, surveillance and follow-up care programs. The expanded role... Read more


RadNet to Present at the BofA Securities 2023 Leveraged Finance Conference on November 28, 2023

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the BofA Securities 2023 Leveraged Finance Conference in Boca Raton, FL on Tuesday, November 28, 2023 at 11:10 a.m. Pacific Time... Read more


Aspira Women’s Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

CMS approves OvaWatchSM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare &... Read more


Psychemedics Appoints Daniella Mehalik as VP - Finance

ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President... Read more


Check-Cap Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual  General Meeting on Monday, December 18th ISFIYA, Israel, Nov. 27, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), today announced financial results and provided a corporate update for the third quarter and nine months ended September 30, 2023. Check Cup Propose Business Combination Agreement In August 2023, Keystone... Read more


Justera Health Secures Supply Agreement for Emart24 to Expand Global Reach

Toronto, Ontario--(Newsfile Corp. - November 23, 2023) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company") is pleased to announce that its wholly-owned subsidiary, Naturevan Nutrition Ltd. ("Naturevan") has successfully secured a supply agreement to provide its products to Emart24, a renowned retail chain, through its partnership with JS Foods Global (JS Foods), a prominent health food distributor with an expansive operational network in the... Read more


Sera Prognostics to Present at 35th Annual Piper Sandler Healthcare Conference

SALT LAKE CITY, Nov. 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming 35th Annual Piper Sandler Healthcare Conference to be held November 28-30, 2023 in New York City. Doug Fisher, Sera's Chief Business Officer, is scheduled to participate in... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB